The present study evaluated the plasma soluble Aβ42/Aβ40 ratio, but not other AD blood biomarkers such as total-tau or neurofilament light chains, as our aim was to have a measure of brain amyloidosis. This evidence concerns the gene MAPT and Alzheimer disease.